Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinhuai Capsule is a Traditional Chinese Medicine (TCM) formulation developed by Jilin Tianheng Pharmaceutical for the treatment of hyperuricemia and gout. The capsule is derived from botanical extracts, primarily *Scutellaria baicalensis* (Huangqin) and *Sophora japonica* (Huaihua). It functions by lowering serum uric acid levels through the inhibition of xanthine oxidase, the enzyme responsible for uric acid production, and by enhancing renal uric acid excretion through the modulation of urate transporters. It has undergone standardized clinical evaluation in China, progressing to Phase III clinical trials to establish its efficacy and safety profile compared to standard urate-lowering therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qinhuai Capsule.